Boissel; Laurent

Patent Applications and Registrations

Patent applications and USPTO patent grants for Boissel; Laurent.The latest application filed is for "genetically modified nk-92 cells having a safety switch".

Company Profile

6.6.11

Boissel; Laurent - San Diego CA
Boissel; Laurent - Boston MA
Boissel; Laurent - Culver City CA
Boissel; Laurent - Brookline MA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Genetically Modified Nk-92 Cells Having A Safety Switch App 20220062343 - Lee; Tien ; et al.	2022-03-03
Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer Grant 11,207,350 - Lee , et al. December 28, 2	2021-12-28
Chemokine Responsive Activated Natural Killer Cells With Secondary Homing Activation For Verified Targets App 20210324042 - SCHOMER; Nathan ; et al.	2021-10-21
Genetically Modified Nk-92 Cells And Monoclonal Antibodies For The Treatment Of Cancer App 20210236550 - Lee; Tien ; et al.	2021-08-05
Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer Grant 11,000,550 - Lee , et al. May 11, 2	2021-05-11
MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC App 20200347351 - Klingemann; Hans ; et al.	2020-11-05
Modified NK-92 haNK003 cells for the clinic Grant 10,801,013 - Klingemann , et al. October 13, 2	2020-10-13
Genetically Modified Nk-92 Cells And Monoclonal Antiboides For The Treatment Of Cancer App 20200306312 - Lee; Tien ; et al.	2020-10-01
Modified NK-92 haNK003 cells for the clinic Grant 10,774,310 - Klingemann , et al. Sept	2020-09-15
Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer Grant 10,736,921 - Lee , et al. A	2020-08-11
Methods For Treating Merkel Cell Carcinoma (mcc) Using Nk-92 Cells App 20200171087 - Klingemann; Hans ; et al.	2020-06-04
Nk-92 Cells And Il-15 Agonist Combination Therapy App 20200121720 - Klingemann; Hans ; et al.	2020-04-23
Genetically Modified Nk-92 Cells And Monoclonal Antiboides For The Treatment Of Cancer App 20190365816 - Lee; Tien ; et al.	2019-12-05
Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer Grant 10,456,420 - Lee , et al. Oc	2019-10-29
MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC App 20190300854 - Klingemann; Hans ; et al.	2019-10-03
MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC App 20180258397 - Klingemann; Hans ; et al.	2018-09-13
Genetically Modified Nk-92 Cells And Monoclonal Antibodies For The Treatment Of Cancer App 20180193383 - Lee; Tien ; et al.	2018-07-12

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.